Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$25.34|
|52 Week High||US$11.04|
|52 Week Low||US$26.99|
|1 Month Change||-4.38%|
|3 Month Change||6.29%|
|1 Year Change||122.48%|
|3 Year Change||52.65%|
|5 Year Change||262.00%|
|Change since IPO||1,167.00%|
Recent News & Updates
We Think Misonix (NASDAQ:MSON) Has A Fair Chunk Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|MSON||US Medical Equipment||US Market|
Return vs Industry: MSON exceeded the US Medical Equipment industry which returned 24.4% over the past year.
Return vs Market: MSON exceeded the US Market which returned 33.4% over the past year.
Stable Share Price: MSON is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MSON's weekly volatility (5%) has been stable over the past year.
About the Company
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company’s products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator, which is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system that provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications.
Misonix Fundamentals Summary
|MSON fundamental statistics|
Is MSON overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MSON income statement (TTM)|
|Cost of Revenue||US$21.39m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.83|
|Net Profit Margin||-19.55%|
How did MSON perform over the long term?See historical performance and comparison
Is Misonix undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MSON's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MSON's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MSON is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: MSON is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MSON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MSON is good value based on its PB Ratio (3.3x) compared to the US Medical Equipment industry average (4.3x).
How is Misonix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MSON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MSON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MSON's revenue (15.1% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: MSON's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MSON's Return on Equity is forecast to be high in 3 years time
How has Misonix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MSON is currently unprofitable.
Growing Profit Margin: MSON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MSON is unprofitable, and losses have increased over the past 5 years at a rate of 43.1% per year.
Accelerating Growth: Unable to compare MSON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSON is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).
Return on Equity
High ROE: MSON has a negative Return on Equity (-10.71%), as it is currently unprofitable.
How is Misonix's financial position?
Financial Position Analysis
Short Term Liabilities: MSON's short term assets ($59.3M) exceed its short term liabilities ($22.7M).
Long Term Liabilities: MSON's short term assets ($59.3M) exceed its long term liabilities ($41.0M).
Debt to Equity History and Analysis
Debt Level: MSON's debt to equity ratio (33.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MSON's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MSON has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MSON has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 54.1% each year.
What is Misonix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MSON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MSON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MSON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MSON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MSON's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stavros Vizirgianakis (51 yo)
Mr. Stavros George Vizirgianakis, B.Com., has been the Chief Executive Officer of Misonix, Inc. since December 19, 2016 and served as its President since December 19, 2016 until September 2019. Mr. Vizirgi...
CEO Compensation Analysis
Compensation vs Market: Stavros's total compensation ($USD2.76M) is above average for companies of similar size in the US market ($USD1.70M).
Compensation vs Earnings: Stavros's compensation has increased whilst the company is unprofitable.
Experienced Management: MSON's management team is considered experienced (3.8 years average tenure).
Experienced Board: MSON's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Misonix, Inc.'s employee growth, exchange listings and data sources
- Name: Misonix, Inc.
- Ticker: MSON
- Exchange: NasdaqGM
- Founded: 1959
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$441.551m
- Shares outstanding: 17.43m
- Website: https://www.misonix.com
Number of Employees
- Misonix, Inc.
- 1938 New Highway
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/27 22:59|
|End of Day Share Price||2021/10/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.